These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37670929)

  • 1. Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention.
    Hou L; Su K; Zhao J; Li Y
    Int J Gen Med; 2023; 16():3977-3984. PubMed ID: 37670929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nomogram for Predicting In-Stent Restenosis Risk in Patients Undergoing Percutaneous Coronary Intervention: A Population-Based Analysis.
    Luo Y; Tan N; Zhao J; Li Y
    Int J Gen Med; 2022; 15():2451-2461. PubMed ID: 35264881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M; Yan X; Wu W
    BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation.
    Zhao J; Hou L; Zhu N; Huang R; Su K; Lei Y; Li Y
    Int J Gen Med; 2023; 16():69-76. PubMed ID: 36636712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China.
    Li M; Hou J; Gu X; Weng R; Zhong Z; Liu S
    Eur J Med Res; 2022 Jan; 27(1):12. PubMed ID: 35065663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of serum apoA-I with in-stent restenosis in coronary heart disease.
    Wang X; Zhang M; Cheng J; Zhou H
    BMC Cardiovasc Disord; 2022 Aug; 22(1):355. PubMed ID: 35927634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents.
    Wu XA; Xie G; Li XQ; Wu HT; Wang X
    Clin Chim Acta; 2018 Apr; 479():20-24. PubMed ID: 29305846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.
    He W; Xu C; Wang X; Lei J; Qiu Q; Hu Y; Luo D
    BMC Cardiovasc Disord; 2021 Sep; 21(1):435. PubMed ID: 34521385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation.
    Yi M; Tang WH; Xu S; Ke X; Liu Q
    Front Cardiovasc Med; 2022; 9():837330. PubMed ID: 35669469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.
    Zhang L; Wang Y; Zhang Z; Liang H; Wu L; Ni L; Gao G; Yang D; Zhao H; Xiao J
    BMC Cardiovasc Disord; 2021 Sep; 21(1):438. PubMed ID: 34525967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents.
    Zhu Y; Liu K; Chen M; Liu Y; Gao A; Hu C; Li H; Zhu H; Han H; Zhang J; Zhao Y
    Cardiovasc Diabetol; 2021 Jul; 20(1):137. PubMed ID: 34238294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent.
    Wang JL; Qin Z; Wang ZJ; Shi DM; Liu YY; Zhao YX; Yang LX; Cheng WJ; Zhou YJ
    J Geriatr Cardiol; 2018 Feb; 15(2):137-145. PubMed ID: 29662507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation.
    Luo Y; Cui S; Zhang C; Huang R; Zhao J; Su K; Luo D; Li Y
    Int J Gen Med; 2022; 15():1733-1742. PubMed ID: 35221713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using XGBoost for Predicting In-Stent Restenosis Post-DES Implantation: Role of Lymphocyte-to-Monocyte Ratio and Residual Cholesterol.
    Hou L; Su K; He T; Zhao J; Li Y
    Int J Gen Med; 2024; 17():3443-3452. PubMed ID: 39139709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The predictive value of epicardial adipose tissue and inflammatory factors for in-stent restenosis].
    Zhou QN; Lin WH; Jing R; Liu JJ; Shi HY; Yang RF; Gao P; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(47):3732-3736. PubMed ID: 31874499
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.
    Takagi K; Ielasi A; Shannon J; Latib A; Godino C; Davidavicius G; Mussardo M; Ferrarello S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A
    Circ Cardiovasc Interv; 2012 Aug; 5(4):491-8. PubMed ID: 22851528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Early Predictive Value of Circulating Monocytes and Eosinophils in Coronary DES Restenosis.
    Li S; Qiu H; Lin Z; Fan L; Guo Y; Zhang Y; Chen L
    Front Cardiovasc Med; 2022; 9():764622. PubMed ID: 35274009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Homocysteine Level Predictive Capability for Severity of Restenosis Post Percutaneous Coronary Intervention.
    Guo J; Gao Y; Ahmed M; Dong P; Gao Y; Gong Z; Liu J; Mao Y; Yue Z; Zheng Q; Li J; Rong J; Zhou Y; An M; Gu L; Zhang J
    Front Pharmacol; 2022; 13():816059. PubMed ID: 35685647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.